OVARIAN CANCER

An overview of ovarian cancer and pathology [Summary] Ovarian cancer is a common cancer of female genital mutilation one of the incidence of cervical cancer and after cancer of the u...

Cytoreductive surgery in the treatment of ovarian cancer Comprehensive Application and prospects Cytoreductive surgery in the treatment of ovarian cancer Comprehensive Application and prospects Foreign Medical Obstetrics and Gynecology...

Epithelial ovarian cancer in the United States is a relatively rare in Gynecologic Oncology, 2004, there were approximately 25,580 cases of new onset patients, 16,090 cases patients died. The majority of patients with advanced cancer, treatment for surgical resection and postoperative to platinum-based chemotherapy. During the past 10 years, chemotherapy improved survival rates improve, and recurrent tumor treatment more effective. In addition, the genetic risk factors for making in-depth understanding of the prevention strategy to become individualized approach to bilateral tubal women - ovarian surgery. This report summarized the clinical characteristics of epithelial ovarian, after reports focus on the treatment of the latest developments.

Epidemiology and risk factors <BR> epithelial ovarian cancer attributed to the continuous peritoneal surface of malignant ovarian surface epithelium. Ovarian cancer patients with a median age of 60 years, women's average lifetime risk of approximately 1 / 70. A clear family history of breast or ovarian cancer is the most important risk factor, although only about 5% of the women involved in genetic susceptibility could be detected. Maternal and no increased risk of ovarian cancer associated, oral contraceptives, pregnancy, breast-feeding and to reduce the risk. In short, these observational studies show that fertility drugs can increase the risk of ovarian cancer, but the spacing of births and the correction after the period has not confirmed these results. Acceptance of women tubal ligation surgery seems to be no low-risk women, although mechanism is unclear.
SARS <BR> family at the same time or separately a clear family history of breast and ovarian cancer (sometimes occurred in women with a young man), and the two may BRCA1 and BRCA2 genes. BRCA1 and BRCA2 gene on chromosome 17q and 13q, and their gene products involved in DNA repair. Because mutations in the BRCA1 and BRCA2 genetic alleles may either parent since, in a dangerous period for a full assessment of the importance of family history.
Specific ethnic groups, such as the Nordic Jews, implied kinds of BRCA1 and BRCA2 mutations increase the likelihood. Nordic health Jewish women the most common mutations are three species of the 185 delAG BRCA1 mutation on the BRCA1 mutation 5382insC, the 6174delT BRCA2 mutation, the overall incidence rate of approximately 2.5%. However, in the diagnosis of ovarian cancer in the Nordic Jewish women, it was reported that the mutation rate of 26% to 41%. According to reports, with the BRCA1 mutation of women suffering from ovarian cancer for a lifetime risk of 56% to 87%. While recognizing that BRCA1 mutation carriers of any age can be very important in ovarian cancer, BRCA1 mutation of women over the age of onset of ovarian cancer patients with sporadic small.
Like BRCA1, BRCA2 protein in the nucleus, with the combination of protein RAD51 in DNA repair. BRCA2 mutation of women's lifetime risk of breast cancer and BRCA1 mutation carriers similar, with a lifetime risk of ovarian cancer is about 10%. Compared to those with no mutation of the BRCA1 or BRCA2 mutation of men suffering from breast cancer is dangerous, the risk of pancreatic cancer may also increase. Compared with patients with sporadic, of the BRCA1 or BRCA2 mutations among patients with ovarian cancer of the natural history of disease progression seems to be relatively slow.
The increased risk of ovarian cancer the second home of the Lynch syndrome II disease; The disease by DNA mismatch repair genes, such as MSH2 (mutS homolog of 2) or MLH1 (homolog of a mutL) Hereditary non-polyposis colon cancer, usually involving the right colon, sometimes associated with other cancers, for example, endometrial cancer, ovarian cancer or genitourinary tract neoplasms.

BRCA1 or BRCA2 mutation of women's preventive treatment <BR> known to have BRCA1 or BRCA2 mutations of the women, after the completion of the reproductive function by excision of ovarian bilateral tubal lower ovarian cancer risk, in such circumstances, it is the choice of a preventive approach. Since mutation carriers with fallopian tube cancer risk also increased, it is proposed to tubal resection as part of preventive surgery, some scholars to ensure complete resection tubal also considered to hysterectomy. Although preventive bilateral tubal Ovariectomy can reduce the risk of ovarian cancer, BRCA1 and BRCA2 mutations in patients with germ-line seems to be suffering from serous primary peritoneal cancer continued risk, the disease can occur in preventive surgery. For example, in a retrospective study, and formerly reported in the period from 1 to 27, have received preventive Ovariectomy women in the 324 cases in six cases of primary peritoneal serous carcinoma. This disease in clinical and histological similar to the epithelial ovarian cancer were considered to represent the mesothelial surface of malignant transformation. According to reports BRCA1 and BRCA2 mutation of women with bilateral tubal preventive ovary, can reduce the risk of breast cancer, its causes may speculate at the same time or separately reduced circulating estrogen and progesterone levels. Accordingly, after whether women should receive estrogen replacement therapy currently still controversial. Discuss other breast cancer risk reduction strategy beyond the scope of this review, for example, in the high-risk population screening, preventive mastectomy or preventive chemotherapy. A pair of ovarian cancer risk factors but unwilling to accept the bilateral tubal women with ovarian preventive, should consider conducting screening, including the regular pelvic examination, serum CA 125 of pelvic and transvaginal sonography. However, it must be emphasized that these strategies are often missed early screening for ovarian cancer, but also in high-risk groups for ovarian cancer screening effectiveness has not yet been confirmed. Similarly, the general risk of ovarian cancer in women (ie no known genetic susceptibility of women), there is no clear evidence that at the same time or separately, including determination of serum CA125 level and pelvic ultrasound examination, routine screening benefits. At least two ongoing randomized clinical trials in ovarian cancer screening on the role of assessment. Finally, in mutation carriers in the use of oral contraceptives to reduce the risk of ovarian cancer benefits is uncertain. Modan, reported in the BRCA1 or BRCA2 mutation of women use oral contraceptives have no preventive benefits, such as Narod Early studies suggested that oral contraceptives may benefit.

Ovarian cancer is a common cancer of female genital mutilation one of the incidence of cervical cancer and after cancer of the ut...

Tags: age, brca1, breast, cancer, carcinoma, cases, cause, chemotherapy, clinical, diagnosis, drug, drugs, early, eat, ert, estrogen, examination, family, gene, group, groups, history, incidence, increased, life, malignant, mutation, ovarian, ovary, patients, pelvic, preventive, protein, rate, reduce, resection, risk, screening, second, study, surface, surgery, surgical, survival, syndrome, therapy, time, treatment, tumor, usually, women